News & Updates

Show Multimedia Only

Adverse pregnancy outcomes tied to increased maternal risk of subarachnoid haemorrhage

21 Jun 2026

Women with a history of adverse pregnancy outcomes are at heightened risk of subarachnoid haemorrhage, as suggested in a study.

Adverse pregnancy outcomes tied to increased maternal risk of subarachnoid haemorrhage

21 Jun 2026

OSA linked to thromboembolic event risk among women with PCOS

20 Jun 2026

Women with polycystic ovarian syndrome (PCOS) may have an increased risk of thromboembolic events in the presence of obstructive sleep apnoea (OSA), according to a retrospective study.

OSA linked to thromboembolic event risk among women with PCOS

20 Jun 2026

Inhaled treprostinil confers benefit in idiopathic pulmonary fibrosis

20 Jun 2026 by

Treatment with inhaled treprostinil helps preserve lung function and delay disease progression in patients with idiopathic pulmonary fibrosis (IPF), according to phase 3 data from the TETON-1 trial.

Inhaled treprostinil confers benefit in idiopathic pulmonary fibrosis

20 Jun 2026

Improved cardiometabolic outcomes seen after surgical remission of endogenous hypercortisolism

20 Jun 2026

Cardiometabolic comorbidities have shown improvements following surgery in patients with Cushing syndrome (CS) and those with mild autonomous cortisol secretion (MACS), reports a study.

Improved cardiometabolic outcomes seen after surgical remission of endogenous hypercortisolism

20 Jun 2026

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

20 Jun 2026

The use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among adults with obesity and concomitant autoimmune diseases appears to lower the incidence of thromboembolic events, emergency department visits, and mortality, according to a study.

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

20 Jun 2026

Pemvidutide positively IMPACTs patients with MASH

20 Jun 2026 by

Treatment with pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, led to significant improvements in primary noninvasive tests (NITs), such as Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), and weight loss in patients with metabolic dysfunction-associated steatohepatitis (MASH), according to the phase IIb IMPACT trial presented at EASL 2026.

Pemvidutide positively IMPACTs patients with MASH

20 Jun 2026

Discovering the power within through metacognition

20 Jun 2026 by

Metacognition can be understood as a powerful yet often overlooked cognitive ability that allows individuals to manage their thinking processes effectively, even within everyday constraints.

Discovering the power within through metacognition

20 Jun 2026

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

19 Jun 2026

The oral, selective factor D inhibitor vemircopan has shown no evidence of benefit in the treatment of adult patients with acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis in a phase 2 trial.

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

19 Jun 2026

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

19 Jun 2026

Combination therapy with oral spironolactone and low-dose oral minoxidil appears safe and tolerable among adult females with hair loss, reports a study. However, those using one or more blood pressure (BP)-altering medications are at increased risk of hypotension-related symptoms.

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

19 Jun 2026

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026 by

A recent study comparing dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with orforglipron, an oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist (RA), has found superior glycaemic control and weight loss with the latter.

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Adverse pregnancy outcomes tied to increased maternal risk of subarachnoid haemorrhage

Adverse pregnancy outcomes tied to increased maternal risk of subarachnoid haemorrhage

OSA linked to thromboembolic event risk among women with PCOS

OSA linked to thromboembolic event risk among women with PCOS

Inhaled treprostinil confers benefit in idiopathic pulmonary fibrosis

Inhaled treprostinil confers benefit in idiopathic pulmonary fibrosis

Improved cardiometabolic outcomes seen after surgical remission of endogenous hypercortisolism

Improved cardiometabolic outcomes seen after surgical remission of endogenous hypercortisolism

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

Pemvidutide positively IMPACTs patients with MASH

Pemvidutide positively IMPACTs patients with MASH

Discovering the power within through metacognition

Discovering the power within through metacognition

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Orforglipron superior to dapagliflozin in metformin-resistant T2D